Retrospective Analysis of Real-World Elacestrant Use in Two Large Austrian Cancer Centers.

Authors

Lisa Vesenmayer, Simon Udovica, Kerstin Wimmer, Constantin Mannsbart, Katharina Kantner, Ruth Exner, Zsuzsanna Bago-Horvath, Stefan Konrad, Kathrin Strasser-Weippl, Christian F Singer, Leonhard Müllauer, Rupert Bartsch, Maximilian Marhold

Published in

Breast care (Basel, Switzerland). Oct 19, 2026. Epub Oct 19, 2026.

Abstract

Elacestrant is an oral selective estrogen receptor degrader (SERD) approved for the treatment of hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) following progression on endocrine therapy and CDK4/6 inhibitors. While randomized trial data from the EMERALD study demonstrated its clinical benefit, real-world evidence remains limited.
We conducted a retrospective chart review of patients with HR-positive/HER2-negative MBC treated with elacestrant at two large cancer centers in Vienna, Austria. Clinical outcomes and safety were evaluated in routine clinical practice by experienced oncologists.
Elacestrant demonstrated clinically meaningful efficacy in a heavily pretreated patient population of 30 patients with estrogen receptor 1 (ESR1) mutations. Median age was 65 years and the cohort was predominantly postmenopausal (86.7%). Before initiation of elacestrant, patients had received a median of two lines of endocrine therapy and one line of chemotherapy. Co-mutations of ESR1/PIK3CA were present in 33.3% of patients. Median progression-free survival (PFS) was 3.6 months (95% CI 2.96-4.24) and median overall survival was 20.2 months (95% CI 5.04-35.36). In univariate analyses, de novo metastatic disease and the presence of a single ESR1-mutated exon were associated with longer PFS, whereas the ESR1 E380Q mutation was associated with shorter PFS. Adverse events of any grade occured in 46.7% of patients. Within our cohort, a low rate of dose reductions (3.3%) was found. Subsequent therapies after elacestrant mainly consisted of antibody-drug conjugates (36.7% of patients) and chemotherapy (26.7%).
In this real-world cohort, elacestrant showed effectiveness and tolerability similar to data observed in the EMERALD trial. Larger prospective real-world analyses are warranted to further validate these findings and define optimal patient selection.

PMID:
42927396
Bibliographic data and abstract were imported from PubMed on 25 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.